2024-05-03 09:53:55 ET
Summary
- TG Therapeutics beat first quarter revenue expectations and raised the full-year revenue guidance by $40 million at the mid-point.
- Work on the subcutaneous version of Briumvi continues and could represent the next step for increased long-term growth expectations.
- TG plans to start another clinical trial of Briumvi in a second autoimmune disease and the trial of azer-cel is on track to start this year as well.
- The first quarter results and the improved outlook leave less room for doubt about Briumvi's growth trajectory.
...
Read the full article on Seeking Alpha
For further details see:
TG Therapeutics: Less Room For Doubt About Briumvi